

## Special Issue

# Immunization of Immunosuppressed Patients

### Message from the Guest Editors

Mass vaccination campaigns have largely mitigated the healthcare burden of COVID-19, and booster vaccinations are being regularly updated. Nevertheless, vaccine response and efficacy remain suboptimal, mainly in those who need care the most, i.e., immunocompromised patients. In this Special Issue, we will analyze the effectiveness of different COVID-19 vaccine formulations across different cohorts of immunocompromised patients. Cohorts will range from oncohematological patients to solid organ transplant recipients to patients with autoimmune disorders. The Special Issue welcomes original research studies on novel vaccine approaches (e.g., mucosal delivery or novel adjuvants) and epidemiological studies or rigorous systematic reviews on vaccine efficacy in particular cohorts of immunocompromised patients. We look forward to receiving your contributions.

---

### Guest Editors

Dr. Massimo Franchini

Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy

Dr. Daniele Focosi

North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

---

### Deadline for manuscript submissions

31 July 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/219379](https://mdpi.com/si/219379)

*Vaccines*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).